Board Appointment

Fulcrum Pharma PLC
07 March 2006


For immediate release                                               7 March 2006

                               FULCRUM PHARMA PLC
                  ('Fulcrum' or 'the Group' or 'the Company')

                               Board Appointment


Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcing
services company, is pleased to announce that Angus Bell will join the Board of
Fulcrum as a Non-Executive Director with effect from 9th March 2006.

Dr Angus Bell, aged 57, has more than thirty years experience in the
pharmaceutical industry including a number of strategic and management roles at
Quintiles and Glaxo.

At Quintiles, the global leader in pharmaceutical services, Dr Bell was Chief
Operating Officer for Preclinical Services and General Manager of Early
Development and Laboratory Services at their Edinburgh facility.  Additionally
he established an early development consultancy service within the company.

Earlier in his career Dr Bell worked at Glaxo where he made significant
contributions to the design and development of several marketed medicines
(Zantac(TM), Imigran(TM), Zofran(TM) and Serevent(TM)).
After the formation of Glaxo Wellcome, Dr Bell led a programme to re-design the
key business processes of R&D including drug candidate selection, clinical
development, and new product delivery.

Currently Dr Bell is a Non-Executive Director of Pharmaceutical Profiles Ltd, a
unique phase I clinical CRO offering improved decision making in early clinical
development. In 2005, following the MBO of the company from its founders, Dr
Bell acted as interim CEO. He also serves as Non-Executive Director of Maccine
Pty Ltd., a Singapore-based preclinical services company.

Jon Court, Chief Executive of Fulcrum Pharma, said: 'I am delighted to
welcome Angus to the Board.  Angus brings a wealth of experience to Fulcrum
particularly in the preclinical arena.  Recently Fulcrum announced that it
planned to strengthen the Board with additional expertise from the service
sector.  We feel that Angus' experience, in particular that gained from
his various roles at Quintiles, will be instrumental in helping Fulcrum drive
the Company's global service model further forward and maximise the
exciting opportunities that lie ahead.'

Angus Bell said: 'Fulcrum offers a unique approach to global services
around drug development.  I am very excited about joining the Board and applying
my knowledge and expertise to Fulcrum's business strategy and core
operations.'

Fulcrum confirms that, save for the above, there are no other matters under
paragraph (g) of Schedule 2 of the AIM rules to be announced.


For further information, please contact:

Fulcrum Pharma PLC                                           Tel: [phone]
Jon Court, Chief Executive

Buchanan Communications                                      Tel: [phone]
Mary-Jane Johnson


Notes for editors


About Fulcrum Pharma plc

Fulcrum Pharma plc is an independent, drug development company that is the first
to offer global virtual drug development and strategic outsourcing services to
the pharmaceutical industry.  The Group has expertise in the design, execution
and delivery of drug development programmes and relies on state of the art
information technology and infrastructure in the supply of its services.

Through Fulcrum's services to its clients, the Directors believe that
there is the capacity to deliver products faster and more efficiently to the
global pharmaceutical market. Fulcrum does this by using its skills in the
design of drug programmes that deliver the necessary information for
decision-making and product registration. In so doing, Fulcrum works closely
with its clients to meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange having successfully floated in March 2000.




                      This information is provided by RNS
            The company news service from the London Stock Exchange